Staphylococcus aureus and Streptococcus pneumoniae interaction and response to pneumococcal vaccination: Myth or reality?

abstract：:The licensed meningococcal serogroup B vaccine, 4CMenB (Bexsero(®)), contains recombinant membrane proteins (rMenB) and outer membrane vesicles (OMV) of the New Zealand serogroup B strain. We investigated whether reducing the OMV and/or protein content influences 4CMenB immunogenicity and reactogenicity in healthy two...

journal_title：Human vaccines & immunotherapeutics

authors： Esposito S,Prymula R,Zuccotti GV,Xie F,Barone M,Dull PM,Toneatto D

更新日期：2014-01-01 00:00:00

abstract：:Higher-valent pneumococcal conjugate vaccines (PCVs) were licensed from 2009 in Europe; similar worldwide clinical effectiveness was observed for PCVs in routine use. Despite a proven medical need, PCV vaccination in Southern Europe remained suboptimal until 2015/16. We searched PubMed for manuscripts published betwee...

journal_title：Human vaccines & immunotherapeutics

authors： Moreira M,Castro O,Palmieri M,Efklidou S,Castagna S,Hoet B

更新日期：2017-06-03 00:00:00

abstract：:The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3-8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA m...

journal_title：Human vaccines & immunotherapeutics

authors： Gilca V,Sauvageau C,Panicker G,De Serres G,Schiller J,Ouakki M,Unger ER

更新日期：2019-01-01 00:00:00

abstract：:Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT00468858). We describe cell-mediated immune (CMI) responses; safety and ...

journal_title：Human vaccines & immunotherapeutics

authors： Moris P,Bauer KM,Currier JR,Friberg H,Eckels KH,Esquilin IO,Gibbons RV,Innis BL,Jarman RG,Simasathien S,Sun P,Thomas SJ,Watanaveeradej V

更新日期：2019-01-01 00:00:00

abstract：:How countries, particularly low- and middle-income economies, should pay the coronavirus disease 2019 (COVID-19) vaccine is an important and understudied issue. We undertook an online survey to measure the willingness-to-pay (WTP) for a COVID-19 vaccine and its determinants in Indonesia. The WTP was assessed using a s...

journal_title：Human vaccines & immunotherapeutics

authors： Harapan H,Wagner AL,Yufika A,Winardi W,Anwar S,Gan AK,Setiawan AM,Rajamoorthy Y,Sofyan H,Vo TQ,Hadisoemarto PF,Müller R,Groneberg DA,Mudatsir M

更新日期：2020-12-01 00:00:00

abstract：:In tick-borne encephalitis (TBE)-endemic regions, long-term vaccination programs are efficient in preventing the disease. A booster dose of a polygeline-free inactivated TBE vaccine (Encepur Adults, GSK), administered approximately 3 years post-primary vaccination according to 1 of 3 licensed vaccination schedules in ...

journal_title：Human vaccines & immunotherapeutics

authors： Costantini M,Callegaro A,Beran J,Berlaimont V,Galgani I

更新日期：2020-09-01 00:00:00

abstract：:The practice of passive immunization with human immune globulin (IG) for the control of communicable diseases (measles, rubella and hepatitis A) differs somewhat between Australia, the United States of America, the United Kingdom, and New Zealand despite the many similarities of these countries, including disease inci...

journal_title：Human vaccines & immunotherapeutics

authors： Young MK,Cripps AW

更新日期：2013-09-01 00:00:00

abstract：:Leukemia-associated antigens such as proteinase-3 (PR3) and Wilms' tumor protein-1 (WT-1) are potential targets of T-cell responses, which can be monitored by T-cell assays within vaccination trials and after allogeneic stem cell transplantation (SCT). In chronic myeloid leukemia (CML) an aberrant cytokine profile of ...

journal_title：Human vaccines & immunotherapeutics

authors： Flörcken A,van Lessen A,Terwey TH,Dörken B,Arnold R,Pezzutto A,Westermann J

更新日期：2013-06-01 00:00:00

abstract：:Hepatitis B virus (HBV) remains a challenging public-health issue in China. Hepatitis B carriers and patients suffer not only physically but also experience strong discrimination and stigma. China's rural population is 629 million. Thus, there is a great need to understand the situation surrounding HBV-related discrim...

journal_title：Human vaccines & immunotherapeutics

authors： Yu L,Wang J,Zhu D,Leng A,Wangen KR

更新日期：2016-01-01 00:00:00

abstract：:It has been theorized that Calmette-Guérin bacillus may prevent or reduce the severity of COVID-19 through a nonspecific stimulation of the immune system. A preliminary assessment of SARS-CoV-2 infection rates and outcomes among 2803 individuals affected with high risk non-muscle-invasive bladder cancer and treated wi...

journal_title：Human vaccines & immunotherapeutics

authors： Fedeli U,Porreca A,Colicchia M,Schievano E,Artibani W,Biasio LR,Palù G

更新日期：2020-09-03 00:00:00

abstract：:Since 2006, some Italian Regions introduced the active offer of measles, mumps, rubella, and varicella (MMRV) vaccine for all newborns during the second years of life. In 2011, Italian Drug Authority (AIFA) recommended the discontinuation of the MMRV use for an increased risk of febrile seizures following vaccination;...

journal_title：Human vaccines & immunotherapeutics

authors： Stefanizzi P,De Nitto S,Patano F,Bianchi FP,Ferorelli D,Stella P,Ancona D,Bavaro V,Tafuri S

更新日期：2020-08-02 00:00:00

abstract：:The purpose of this study is to mine CAR-T patents and therapies under development, to design a landscape of the sector and to understand key therapy segments and their current trends. The study analyzed the entire market, consisting of 1624 patent families and 509 biologics under development, to depict an overview of...

journal_title：Human vaccines & immunotherapeutics

authors： Picanco-Castro V,Gonçalves Pereira C,Swiech K,Ribeiro Malmegrim KC,Tadeu Covas D,Silveira Porto G

更新日期：2020-06-02 00:00:00

abstract：:Raising high titer antibodies in animals is usually performed by protein immunization, which requires the long and sometimes difficult step of production of the recombinant protein. DNA immunization is an alternative to recombinant proteins, only requiring the building of an eukaryotic expression plasmid. Thanks to ef...

journal_title：Human vaccines & immunotherapeutics

authors： Burgain A,Rochard A,Trollet C,Mazuet C,Popoff MR,Escriou V,Scherman D,Bigey P

更新日期：2013-10-01 00:00:00

abstract：:Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is a first in a series dedicated to evaluate the status of current global clinical pipeline for cancer vaccines. Apart from specific areas of medical need which can be addressed by cancer vaccines, the a...

journal_title：Human vaccines & immunotherapeutics

authors： Kudrin A,Hanna MG Jr

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:We studied completeness and timeliness of vaccination and determinants for low and delayed uptake in children born between 2008 and 2009 in Zhejiang province in eastern China. METHODS:We used data from a cross-sectional cluster survey conducted in 2011, which included 1146 children born from 1 Jan 2008 to 3...

journal_title：Human vaccines & immunotherapeutics

authors： Hu Y,Chen Y,Guo J,Tang X,Shen L

更新日期：2014-01-01 00:00:00

abstract：:Zika is an arboviral illness caused by infection with the Zika flavivirus. Transmission most commonly occurs during a feeding event involving an infected Aedes mosquito or vertical transmission between an infected mother to her fetus. Infection outcomes range from asymptomatic to devastating neurologic injuries in chi...

journal_title：Human vaccines & immunotherapeutics

authors： Thomas SJ,Barrett A

更新日期：2020-10-02 00:00:00

abstract：:Post licensure surveillance of adverse events following immunization (AEFI) is a fundamental activity to improve safety and maintain public confidence in vaccines.   Since 2011, the Liguria Region has been involved in the inter-regional project of post-marketing surveillance of AEFI, coordinated by the Italian Medicin...

journal_title：Human vaccines & immunotherapeutics

authors： Alicino C,Merlano C,Zappettini S,Schiaffino S,Della Luna G,Accardo C,Gasparini R,Durando P,Icardi G

更新日期：2015-01-01 00:00:00

abstract：:Malaria remains one of the most significant infectious diseases worldwide. Concordant with scaled intervention efforts and the emphasis of elimination and eradication on the agenda of many malaria control programs, the development of a malaria vaccine that reduces transmission of the parasite from human host to mosqui...

journal_title：Human vaccines & immunotherapeutics

authors： Nixon CP

更新日期：2016-12-01 00:00:00

abstract：:Different strategies have been proposed for the development of protein subunit vaccine candidates for tuberculosis (TB), which shows better safety than other types of candidates and the currently used Bacillus Calmette-Guérin (BCG) vaccine. In order to develop more effective protein subunits depending on the mechanism...

journal_title：Human vaccines & immunotherapeutics

authors： Teng X,Tian M,Li J,Tan S,Yuan X,Yu Q,Jing Y,Zhang Z,Yue T,Zhou L,Fan X

更新日期：2015-01-01 00:00:00

abstract：:Japanese encephalitis (JE) is a serious public health concern in most of Asia. The disease is caused by JE virus (JEV), a flavivirus transmitted by Culex mosquitoes. Several vaccines have been developed to control JE in endemic areas as well as to protect travelers and military personnel who visit or are commissioned ...

journal_title：Human vaccines & immunotherapeutics

authors： Hegde NR,Gore MM

更新日期：2017-06-03 00:00:00

abstract：:Influenza vaccination is the most effective way of preventing influenza infections but its coverage is extremely low in China. Poor influenza vaccine effectiveness (VE) was reported in the 2014/15 season in some Northern Hemisphere countries with a predominance of H3N2 viruses belonging to the 3C.2a clade. However, th...

journal_title：Human vaccines & immunotherapeutics

authors： Ma C,Pan Y,Zhang L,Zhang Y,Wu S,Sun Y,Duan W,Zhang M,Wang Q,Yang P

更新日期：2017-10-03 00:00:00

abstract：:Despite the long-term efficacy and immune persistence observed following HBV vaccination of infants, the need for a booster dose following infant immunization continues to be deliberated. Evidence from HBV booster dose response studies and long-term immunization program reviews are the basis for the recommendation tha...

journal_title：Human vaccines & immunotherapeutics

authors： Osiowy C

更新日期：2018-01-01 00:00:00

abstract：:Aim: This research investigated the therapeutic effect of an allogeneic mouse brain microvascular endothelial cell vaccine on lung cancer and further elucidated its potential anti-angiogenic mechanism. Materials & methods: The immune effect of the allogeneic bEnd.3 vaccine and DC vaccine loaded with bEnd.3 antigen on ...

journal_title：Human vaccines & immunotherapeutics

authors： Zhao J,Zhang X,Du Y,Zhou L,Dong Z,Zhao J,Lu J

更新日期：2020-05-27 00:00:00

abstract：:This survey study compared pre- and post-pandemic knowledge, attitudes, beliefs, and intended behaviors of pregnant women regarding influenza vaccination (seasonal and/or pandemic) during pregnancy in order to determine key factors influencing their decision to adhere to influenza vaccine recommendations. Only 36% of ...

journal_title：Human vaccines & immunotherapeutics

authors： Halperin BA,MacKinnon-Cameron D,McNeil S,Kalil J,Halperin SA

更新日期：2014-01-01 00:00:00

abstract：:Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TD...

journal_title：Human vaccines & immunotherapeutics

authors： Tran NH,Chansinghakul D,Chong CY,Low CY,Shek LP,Luong CQ,Fargo C,Wartel TA,Sun S,Skipetrova A,Bouckenooghe A

更新日期：2019-01-01 00:00:00

abstract：:The four-component meningococcal serogroup B vaccine (4CMenB) contains antigens present in the majority of meningococci causing invasive meningococcal disease (IMD) and may potentially offer protection against strains belonging to non-B serogroups. This study aimed to evaluate the ability of 4CMenB-induced antibodies ...

journal_title：Human vaccines & immunotherapeutics

authors： Fazio C,Biolchi A,Neri A,Tomei S,Vacca P,Ambrosio L,Palmieri A,Mori E,La Gaetana R,Pizza M,Giuliani MM,Serino L,Stefanelli P

更新日期：2021-01-31 00:00:00

abstract：:Neisseria meningitidis or meningococcus is divided into 12 distinct serogroups of which A, B, C, W, X, and Y are medically most important and cause health problems in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Globally, serogroup A has be...

journal_title：Human vaccines & immunotherapeutics

authors： Bröker M,Emonet S,Fazio C,Jacobsson S,Koliou M,Kuusi M,Pace D,Paragi M,Pysik A,Simões MJ,Skoczynska A,Stefanelli P,Toropainen M,Taha MK,Tzanakaki G

更新日期：2015-01-01 00:00:00

abstract：:Background: We performed a systematic review to evaluate factors affecting uptake of rotavirus vaccine amongst physicians, parents and health system. Methods: We identified 15 studies that met the inclusion criteria from 790 screened studies published between Jan 2005 to Jan 2016. Results: Perceived severity of rotavi...

journal_title：Human vaccines & immunotherapeutics

authors： Apte A,Roy S,Bavdekar A,Juvekar S,Hirve S

更新日期：2018-01-01 00:00:00

abstract：:Purpose: Gaps remain in the public's knowledge of the human papillomavirus (HPV). We assessed racial/ethnic and gender disparities in knowledge and awareness of HPV and the HPV vaccine among US adults. METHODS:Data from the Health Information National Trends Survey 4 Cycle 3 (September - December 2013) and Cycle 4 (A...

journal_title：Human vaccines & immunotherapeutics

authors： Adjei Boakye E,Tobo BB,Rojek RP,Mohammed KA,Geneus CJ,Osazuwa-Peters N

更新日期：2017-11-02 00:00:00

abstract：:A new live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) has been developed based on innovative technology to give protection against JE with an improved immunogenicity and safety profile. In this phase 3, observer-blind study, 274 children aged 12-24 months were randomized 1:1 to receive one dose of...

journal_title：Human vaccines & immunotherapeutics

authors： Kim DS,Houillon G,Jang GC,Cha SH,Choi SH,Lee J,Kim HM,Kim JH,Kang JH,Kim JH,Kim KH,Kim HS,Bang J,Naimi Z,Bosch-Castells V,Boaz M,Bouckenooghe A

更新日期：2014-01-01 00:00:00